Charles River Laboratories International (NYSE:CRL) Price Target Lowered to $165.00 at JPMorgan Chase & Co.

Charles River Laboratories International (NYSE:CRL) had its target price trimmed by JPMorgan Chase & Co. from $175.00 to $165.00 in a research report released on Thursday morning,Benzinga reports. The firm currently has a neutral rating on the medical research company’s stock.

Several other analysts have also issued reports on the company. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. UBS Group restated a “neutral” rating and issued a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Morgan Stanley cut their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Finally, Barclays cut their price objective on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a report on Tuesday. Three analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $195.71.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $162.63 on Thursday. The company has a market capitalization of $8.32 billion, a P/E ratio of 20.35, a price-to-earnings-growth ratio of 6.01 and a beta of 1.37. The company’s 50-day moving average is $173.39 and its 200 day moving average is $188.81. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. Charles River Laboratories International has a fifty-two week low of $150.79 and a fifty-two week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company’s revenue was down 1.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.46 EPS. On average, equities research analysts forecast that Charles River Laboratories International will post 10.16 earnings per share for the current year.

Hedge Funds Weigh In On Charles River Laboratories International

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Versant Capital Management Inc boosted its position in shares of Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. raised its stake in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares in the last quarter. Assetmark Inc. lifted its position in Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares during the last quarter. Optiver Holding B.V. bought a new stake in Charles River Laboratories International during the fourth quarter valued at approximately $37,000. Finally, GeoWealth Management LLC grew its stake in Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock worth $46,000 after buying an additional 190 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).